Spinal muscular atrophy
Drug research and approvals for spinal muscular atrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 79 studies of spinal muscular atrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 22 drug trials for it since 2013, FDA has 6 approved and 12 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 79
- Trials authorized in Canada: 22
- FDA orphan approvals: 6
- EU medicines: 4
Recruiting Now
Newest start dates first, of 79 recruiting on ClinicalTrials.gov ↗- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- A Registry of Cases of Spinal Muscular AtrophyNCT07805278 · Not reported · St. Jude Children's Research Hospital · starts Nov 1, 2026
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy…NCT07444450 · Phase 3 · Biogen · starts Oct 31, 2026
- Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMANCT07822711 · Not applicable · Peking University Third Hospital · starts Oct 22, 2026
- A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal…NCT07767890 · Not reported · Novartis Pharmaceuticals · starts Oct 7, 2026
- Sarcopenia and Interlaminar Epidural Steroid Injection Outcomes in Lumbar Spinal StenosisNCT07855419 · Not reported · Marmara University · starts Oct 2, 2026
- Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System DisordersNCT07900672 · Not reported · Ambulanzpartner Soziotechnologie APST GmbH · starts Oct 1, 2026
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years…NCT07444476 · Phase 3 · Biogen · starts Sep 8, 2026
- ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal…NCT07448610 · Phase 4 · Novartis Pharmaceuticals · starts Aug 27, 2026
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously…NCT07723248 · Phase 3 · ORIC Pharmaceuticals · starts Aug 3, 2026
Trials Authorized in Canada
The 10 newest of 22; search them all in Canada trials| May 11, 2026 | A phase 3, randomized, double-blinded study to evaluate the safety and efficacy of salanersen (biib115) after onasemnogene abeparvovec treatment in infants…SALANERSEN (BIIB115) | Biogen | Pending |
| Mar 20, 2026 | An open-label, phase 3 study to evaluate the efficacy and safety of salanersen (biib115) in participants aged 15–60 years with spinal muscular atrophy who are…SALANERSEN (BIIB115) | Biogen | Pending |
| Dec 15, 2025 | A phase 2 double-blinded, randomized, placebo-controlled study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of…ARGX-119 | argenx US, Inc. | Pending |
| Dec 20, 2023 | A phase II, open-label study to investigate the pharmacokinetics and safety, of risdiplam (ro7034067) in infants with spinal muscular atrophyRISDIPLAM | Roche | Closed |
| Sep 12, 2023 | A two-part, seamless, multi-center, randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics,…GYM329 (RO7204239) / RISDIPLAM | Roche | Ongoing |
| Apr 11, 2023 | A phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of nmd670 in ambulatory…NMD670 | NMD PHARMA A/S | Closed |
| Aug 5, 2022 | Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of oav101 administered intrathecally (1.2 x 1014…ZOLGENSMA | Novartis Pharmaceuticals Corporation | Closed |
| Apr 20, 2022 | A long-term extension study of nusinersen (biib058) administered at higher doses in participants with spinal muscular atrophy who previously participated in an…NUSINERSEN (BIIB058) | Biogen | Closed |
| Aug 4, 2021 | An open label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophyRISDIPLAM | Roche | Closed |
| Jun 24, 2021 | A phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with…ZOLGENSMA | Novartis Pharmaceuticals Corporation | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 18| Sep 11, 2026 | Isembyldtreatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival… | Scholar Rock | Approved |
| Nov 24, 2025 | Itvismatreatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival… | Novartis Gene Therapies, Inc. | Approved |
| May 27, 2022 | EvrysdiTreatment of spinal muscular atrophy (SMA) in pediatric and adult patients | Genentech, Inc., a Member of the Roche Group | Approved |
| Aug 7, 2020 | Evrysditreatment of spinal muscular atrophy (SMA) in patients 2 months of age and older | Genentech, Inc., a Member of the Roche Group | Approved |
| May 24, 2019 | ZOLGENSMAIndicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in… | Novartis Gene Therapies, Inc. | Approved |
| Dec 23, 2016 | SpinrazaTreatment of spinal muscular atrophy in pediatric and adult patients | Biogen, Inc | Approved |
| Nov 10, 2025 | self-complementary recombinant adeno-associated viral…treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older | Beijing Genecradle Therapeutics Co., Ltd. | Designated |
| Jul 23, 2025 | pegylated insulin-like growth factor 1 (PEG-IGF1)treatment of spinal muscular atrophy (SMA) | Sarcomed AB | Designated |
| Jan 22, 2024 | antisense oligonucleotide (ASO) binding SMN2 pre-mRNATreatment of Spinal Muscular Atrophy | Biogen | Designated |
| Dec 16, 2022 | Taldefgrobep AlfaTreatment of spinal muscular atrophy | Biohaven Pharmaceuticals, Inc. | Designated |
| Dec 7, 2021 | A humanized monoclonal IgG1-based antibody which binds to…Treatment of Spinal Muscular Atrophy (SMA) | Genentech Inc. | Designated |
| Nov 24, 2020 | Single-stranded, non-replicating recombinant…Treatment of spinal muscular atrophy with respiratory distress type 1 (SMARD1) | Abigail Wexner Research Institute, Nationwide Children’s Hospital | Designated |
| Mar 4, 2020 | Phosphorodiamidate morpholino oligomer (5¿-…Treatment of Spinal Muscular Atrophy | Shift Pharmaceuticals Holdings, Inc. | Designated |
| May 11, 2017 | fast skeletal muscle troponin activatorTreatment of spinal muscular atrophy | Cytokinetics, Inc. | Designated |
| Oct 18, 2011 | sodium 4-phenylbutyrateTreatment of spinal muscular atrophy | GMP-Orphan SAS | Designated |
Medicines Authorised in the EU
Newest first| Jun 30, 2026 | Itvismaonasemnogene abeparvovec | Novartis Europharm Limited | EMA ↗ |
| Mar 26, 2021 | Evrysdirisdiplam | Roche Registration GmbH | EMA ↗ |
| May 18, 2020 | Zolgensmaonasemnogene abeparvovec · orphan | Novartis Europharm Limited | EMA ↗ |
| May 30, 2017 | Spinrazanusinersen · orphan | Biogen Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA